Wells Fargo & Company Corvus Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 265 shares of CRVS stock, worth $577. This represents 0.0% of its overall portfolio holdings.
Number of Shares
265
Previous 260
1.92%
Holding current value
$577
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CRVS
# of Institutions
51Shares Held
18.3MCall Options Held
29.9KPut Options Held
30.2K-
Orbimed Advisors LLC San Diego, CA6.94MShares$15.1 Million0.28% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$7.14 Million2.56% of portfolio
-
Samlyn Capital, LLC New York, NY2.35MShares$5.12 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$3.26 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny637KShares$1.39 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $101M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...